<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isoniazid: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isoniazid: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isoniazid: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8577" href="/d/html/8577.html" rel="external">see "Isoniazid: Drug information"</a> and <a class="drug drug_patient" data-topicid="10774" href="/d/html/10774.html" rel="external">see "Isoniazid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708956"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatitis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported and may occur or may develop even after many months of treatment. The risk of developing hepatitis is age related. Approximate case rates by age are as follows: less than 1/1,000 for persons younger than 20 years of age, 3/1,000 for persons in the 20 to 34 year age group, 12/1,000 for persons in the 35 to 49 year age group, 23/1,000 for persons in the 50 to 64 year age group, and 8/1,000 for persons older than 65 years. The risk of hepatitis is increased with daily consumption of alcohol. Precise data to provide a fatality rate for isoniazid-related hepatitis are not available; however, in a US Public Health Service surveillance study of 13,838 persons taking isoniazid, there were 8 deaths among 174 cases of hepatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Therefore, carefully monitor patients given isoniazid and interview patients at monthly intervals. For persons 35 years and older, in addition to monthly symptom reviews, measure hepatic enzymes (specifically, AST and ALT) prior to starting isoniazid therapy and periodically throughout treatment. Isoniazid-associated hepatitis usually occurs during the first 3 months of treatment. Usually, enzyme levels return to normal despite continuance of drug, but, in some cases, progressive liver dysfunction occurs. Other factors associated with an increased risk of hepatitis include daily use of alcohol, chronic liver disease, and injection drug use. A recent report suggests an increased risk of fatal hepatitis associated with isoniazid among women, particularly black and Hispanic women. The risk may also be increased during the postpartum period. Consider more careful monitoring in these groups, possibly including more frequent laboratory monitoring. If abnormalities of liver function exceed 3 to 5 times the upper limit of normal (ULN), strongly consider discontinuation of isoniazid. Liver function tests are not a substitute for a clinical evaluation at monthly intervals or for the prompt assessment of signs or symptoms of adverse reactions occurring between regularly scheduled evaluations. Instruct patients to immediately report signs or symptoms consistent with liver damage or other adverse reactions. These include any of the following: unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesia of the hands and feet, persistent fatigue, weakness or fever of greater than 3-day duration or abdominal tenderness, especially right upper quadrant discomfort. If these symptoms appear or if signs suggestive of hepatic damage are detected, promptly discontinue isoniazid, because continued use of the drug in these cases has been reported to cause a more severe form of liver damage.</p>
<p style="text-indent:-2em;margin-left:2em;">Give patients with tuberculosis who have hepatitis attributed to isoniazid appropriate treatment with alternative drugs. If isoniazid must be reinstituted, do so only after symptoms and laboratory abnormalities have cleared. Restart the drug in very small and gradually increasing doses and withdraw immediately if there is any indication of recurrent liver involvement.</p>
<p style="text-indent:-2em;margin-left:2em;">Defer preventive treatment in persons with acute hepatic diseases.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867267"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Isotamine [DSC];</li>
<li>PDP-Isoniazid</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048065"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antitubercular Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F184805"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Concomitant pyridoxine is recommended in patients at risk for isoniazid-induced neuropathy, including breastfeeding infants and patients who are pregnant or have HIV, diabetes, malnutrition, alcoholism, or chronic renal failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-WHO.3'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="509afd07-0b2a-43fd-99c3-f4effbfdeaa4">Tuberculosis, active; treatment for drug-susceptible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, active; treatment for drug-susceptible</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Always use in combination with other antitubercular drugs. Any regimens using less than once-daily dosing should administer dosing as directly observed therapy (DOT). Some experts recommend DOT for all pediatric patients. Isoniazid dosing differs depending on frequency of dosing/treatment regimen selected; consult current guidelines for detailed information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<i> Once daily or 5 times weekly (DOT): </i></i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;15 years, weighing ≤40 kg: Oral, IM: 10 to 15 mg/kg/dose once daily (or 5 days/week by DOT); maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral, IM: 5 mg/kg/dose once daily (or 5 days/week by DOT); typical dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three-times-weekly DOT: </i>
<b>Note:</b> Three-times-weekly DOT may be used as an alternative to daily therapy in patients without HIV with noncavitary and/or smear-negative disease. Though three-times-weekly regimen is preferred to twice-weekly, data to guide dosing are limited; suggested dosing based on twice-weekly regimen.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;15 years, weighing ≤40 kg: Oral, IM: 20 to 30 mg/kg/dose three times weekly by DOT; maximum dose: 900 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral, IM: 15 mg/kg/dose three times weekly by DOT (typical dose: 900 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Twice-weekly DOT: </i>
<b>Note:</b> Regimen not generally recommended; do not use in HIV patients or those with smear-positive and/or cavitary disease, and only use after completion of a 2-week once-daily (or 5-times-weekly) regimen in the intensive phase. Missed doses result in the equivalent of once-weekly dosing which has been shown to be inferior and is associated with treatment failure, relapse, and development of drug resistance.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;15 years, weighing ≤40 kg: Oral, IM: 20 to 30 mg/kg/dose twice weekly by DOT; maximum dose: 900 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral, IM: 15 mg/kg/dose twice weekly by DOT; typical dose: 900 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy: </i>Treatment regimens consist of an initial 2-month intensive phase of a 4-drug regimen, followed by a continuation phase of isoniazid and rifampin. Duration of continuation phase is ≥4 months; should be longer for cavitary disease with positive cultures at completion of intensive phase (7 months), bone and joint disease (≥4 to 7 months), and CNS disease (7 to 10 months).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8eb3962-5162-4e88-b866-0b980f4769e9">Tuberculosis, active; treatment for drug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, active; treatment for drug-resistant: Note:</b> Use should only be considered in patients with low-level isoniazid resistance; do not use in patients with high-level isoniazid resistance. Always use in combination with other antitubercular drugs; expert consultation for optimal regimen and duration of treatment is advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IM: 15 to 20 mg/kg/day as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-29995958','lexi-content-ref-WHO.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-29995958','lexi-content-ref-WHO.4'])">Ref</a></span>). Administer in combination with pyridoxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc4b7ff-370a-47a0-abc7-37f2dedcc154">Tuberculosis, latent infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, latent infection; treatment:</b> Preferred regimen varies between guidelines and based on patient characteristics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584'])">Ref</a></span>); regimens should not be used in patients known or presumed to be infected with resistant strains of tuberculosis (TB) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid combination therapy:</i>
<b>Note: </b>Preferred regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Rifapentine combination: Independent of HIV status: <b>Note: </b>May be administered by DOT or self-administered therapy (SAT) at the clinician's discretion based on local practice, patient attributes/preferences, and other factors including risk for TB disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29953429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29953429'])">Ref</a></span>). Only use in HIV-infected patients if antiretroviral therapy has acceptable drug-drug interactions with rifapentine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29953429','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29953429','lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 11 years: Oral: Isoniazid 25 mg/kg/dose once weekly for 12 weeks (12 doses); maximum dose: 900 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: Isoniazid 15 mg/kg/dose once weekly for 12 weeks (12 doses), round dose up to nearest 50 or 100 mg; maximum dose: 900 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Rifampin combination: Independent of HIV status: <b>Note: </b>Only use in HIV-infected patients if antiretroviral therapy has acceptable drug-drug interactions with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29953429','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29953429','lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Oral: Isoniazid 10 to 20 mg/kg/dose once daily (maximum dose: 300 mg/dose) for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid monotherapy</i>: <b>Note: </b>Alternative regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents; independent of HIV status:</p>
<p style="text-indent:-2em;margin-left:8em;">Daily regimen: Oral: 10 to 20 mg/kg/dose once daily for 6 to 9 months; maximum dose: 300 mg/dose; while the CDC recommends a 6-month duration, 9 months may be considered; direct comparative efficacy data for 6 months versus 9 months are lacking and risk of hepatotoxicity is greater with longer durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584'])">Ref</a></span>). <b>Note: </b>Some organizations recommend an upper limit of 15 mg/kg/dose (maximum dose: 300 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-30277688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-30277688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Twice-weekly regimen: Oral: 20 to 40 mg/kg/dose twice weekly for 6 to 9 months; maximum dose: 900 mg/dose; must be administered by DOT; while the CDC recommends a 6-month duration, 9 months may be considered; direct comparative efficacy data are lacking for 6 months versus 9 months and risk of hepatotoxicity is greater with longer durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2','lexi-content-ref-32053584'])">Ref</a></span>). <b>Note:</b> Some organizations recommend an upper limit of 30 mg/kg/dose (maximum dose: 900 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-30277688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-30277688'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="963010a4-d849-4865-8b71-9750d75509ad">Pulmonary nontuberculous mycobacterial infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary nontuberculous mycobacterial infection; treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 10 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128342"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Altered kidney function: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-31729908','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-31729908','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Dialyzable. Based on experience in adults, no dosage adjustment necessary; administer after hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51128343"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute liver disease or previous isoniazid-associated hepatic injury: Contraindicated. For latent tuberculosis infection, defer treatment with isoniazid.</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic liver disease: There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution, may accumulate and additional liver damage may occur in patients with preexisting liver disease. Monitor laboratory and clinical parameters frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during therapy (ALT or AST &gt;3 times the ULN)</i>: Discontinue or temporarily withhold treatment.</p></div>
<div class="block doa drugH1Div" id="F184787"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8577" href="/d/html/8577.html" rel="external">see "Isoniazid: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Concomitant pyridoxine is recommended in any patient at risk for neuropathy (eg, patients with HIV infection, diabetes, alcoholism, nutritional deficiency, chronic renal failure, advanced age) and in pregnant or breastfeeding women (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-WHO.3','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-WHO.3','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a14e477-5eab-40b1-b158-a6ebc65a1f53">Tuberculosis disease [active tuberculosis]</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis disease [active tuberculosis]:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug susceptible</i>: <b>Note:</b> Always administer in combination with other antitubercular drugs.</p>
<p style="text-indent:-2em;margin-left:6em;">6-month regimen:</p>
<p style="text-indent:-2em;margin-left:8em;">Once-daily therapy: <b>Oral, IM: </b>5 mg/kg/dose (usual dose: 300 mg) once daily. <b>Note: </b>The preferred frequency of administration is once daily during the intensive and continuation phases; however, 5 days per week administration by directly observed therapy (DOT) is an acceptable alternative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Three-times-weekly DOT: <b>Oral, IM:</b> 15 mg/kg/dose (usual dose: 900 mg) administered 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Twice-weekly DOT: <b>Oral, IM: </b>15 mg/kg/dose (usual dose: 900 mg) administered twice weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Once-weekly DOT: <b>Oral, IM: </b>15 mg/kg/dose (usual dose: 900 mg) administered once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Regimens:</i> Traditional treatment regimens for pulmonary tuberculosis and tuberculous meningitis consist of an initial 2-month phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin for pulmonary tuberculosis and a continuation phase of an additional 7 to 10 months of isoniazid and rifampin for tuberculous meningitis (optimal duration is not defined although continuation phase must continue for a minimum of 7 additional months). Adjunctive corticosteroid therapy (eg, dexamethasone, prednisolone) tapered over 6 to 8 weeks is also recommended for tuberculous meningitis. Isoniazid frequency and dosing differs depending on treatment regimen selected; consult current Drug-sensitive tuberculosis (TB) guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">4-month rifapentine-moxifloxacin-based regimen:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Reserve use for patients ≥40 kg with pulmonary TB who are not pregnant or breastfeeding; for patients with HIV infection, only use if CD4 count ≥100 cells/mm<sup>3</sup> and in patients on an efavirenz-based antiretroviral regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-33951360'])">Ref</a></span>). In the clinical study evaluating this regimen, ≥5 doses per week were given by DOT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33951360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial phase:<b> Oral:</b> 300 mg once daily in combination with rifapentine, moxifloxacin, and pyrazinamide for 8 weeks (56 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-33951360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Continuation phase:<b> Oral:</b> 300 mg once daily in combination with rifapentine and moxifloxacin for 9 weeks (63 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35202353','lexi-content-ref-33951360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35202353','lexi-content-ref-33951360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-resistant (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use should only be considered in patients with low-level isoniazid resistance; do not use in patients with high-level isoniazid resistance. Expert consultation for optimal regimen and duration of treatment is advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IM:</b> 15 mg/kg once daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-31945300','lexi-content-ref-Schluger.1','lexi-content-ref-30698688','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-31945300','lexi-content-ref-Schluger.1','lexi-content-ref-30698688','lexi-content-ref-WHO.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23421342-4ccb-47f4-86a2-b61c9f7f4821">Tuberculosis infection [latent tuberculosis]</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis infection [latent tuberculosis]:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid and rifapentine combination regimen:</i>
<b>Oral:</b> 15 mg/kg/dose (round up to nearest 50 or 100 mg; maximum dose: 900 mg/dose) once weekly in combination with rifapentine for 3 months by DOT (preferred) or self-administered therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29953429','lexi-content-ref-HHS.1','lexi-content-ref-32053584','lexi-content-ref-22150035','lexi-content-ref-27243774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29953429','lexi-content-ref-HHS.1','lexi-content-ref-32053584','lexi-content-ref-22150035','lexi-content-ref-27243774'])">Ref</a></span>). <b>Note:</b> The once-weekly rifapentine-containing regimen may only be used in patients who are not pregnant and/or not expecting to become pregnant; if used in patients with HIV, it may only be used in those receiving antiretroviral therapy (ART) with acceptable drug-drug interactions with rifapentine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29953429','lexi-content-ref-HHS.1','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29953429','lexi-content-ref-HHS.1','lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid and rifampin combination regimen: </i>
<b>Oral:</b> 5 mg/kg (maximum: 300 mg/dose) once daily in combination with rifampin for 3 months. <b>Note:</b> If used in patients with HIV, it may only be used in those receiving antiretroviral therapy with acceptable drug-drug interactions with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid monotherapy (alternative regimen): </i>
<b>Oral, IM:</b> 5 mg/kg (maximum: 300 mg/dose) once daily for 6 or 9 months <b>or</b> 15 mg/kg (maximum: 900 mg/dose) twice weekly under DOT for 6 or 9 months. <b>Note:</b> 9 months of daily isoniazid therapy may be more effective than 6 months, but no clinical trial data are available that directly compare the 2 durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991775"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Acetylator status (eg, slow vs rapid), rather than kidney function, is considered to be the primary contributor to isoniazid clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-391461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-391461'])">Ref</a></span>). Although no dosage adjustments of isoniazid are recommended in patients with end-stage kidney disease, including patients on dialysis, use with caution due to an increased risk of neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27103355','lexi-content-ref-8324207','lexi-content-ref-28870161','lexi-content-ref-31929489','lexi-content-ref-29776936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27103355','lexi-content-ref-8324207','lexi-content-ref-28870161','lexi-content-ref-31929489','lexi-content-ref-29776936'])">Ref</a></span>); close monitoring and concomitant pyridoxine therapy is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-WHO.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, IM:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-27516382','lexi-content-ref-954244','lexi-content-ref-391461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-27516382','lexi-content-ref-954244','lexi-content-ref-391461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Slightly dialyzable (9.2%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10228130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10228130'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-10228130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-10228130'])">Ref</a></span>); when scheduled dose falls on a dialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Slightly dialyzable (CAPD accounts for 1.3% of total clearance): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12968844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12968844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988932"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution, may accumulate and additional liver damage may occur in patients with preexisting liver disease. Contraindicated in patients with acute liver disease or previous isoniazid-associated hepatic injury. For ALT or AST &gt;3 times the ULN: discontinue or temporarily withhold treatment. Treatment with isoniazid for tuberculosis (TB) infection (latent TB) should be deferred in patients with acute hepatic diseases.</p></div>
<div class="block arsc drugH1Div" id="F56917955"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isoniazid is associated with <b>increased serum transaminases, </b>
<b>hyperbilirubinemia</b>, <b>jaundice, </b>and <b>hepatitis</b>. Asymptomatic, transient serum aminotransferase elevations may occur in 10% to 20% of patients, with 3% to 5% of elevations reaching ≥5 times the upper limit of normal less commonly. The pattern of liver injury is typically hepatocellular (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929376'])">Ref</a></span>). Some patients may also present with <b>drug reaction with eosinophilia and systemic symptoms </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26142408','lexi-content-ref-36147124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26142408','lexi-content-ref-36147124'])">Ref</a></span>). Resolution of transaminase elevations often occurs with continued isoniazid use. If isoniazid is discontinued due to liver injury, resolution usually occurs within a week; although, severe and fatal <b>hepatotoxicity </b>may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021358'])">Ref</a></span>). Rechallenge may result in rapid recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6007094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6007094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; accumulation of mono-acetyl hydrazine, a toxic intermediate of its metabolism, has been postulated, as well as an immune-mediated response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur at any time; usually appearing in the first 3 months of therapy. In one retrospective review, a median of 16 weeks from treatment initiation to symptom onset was reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (higher incidence in &gt;50 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1736764','lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1736764','lexi-content-ref-17021358'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heavy alcohol consumption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12539070','lexi-content-ref-666111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12539070','lexi-content-ref-666111'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic hepatitis B or C, or HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929376'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12539070','lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12539070','lexi-content-ref-27516382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Liver transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malnutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12539070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12539070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Postpartum females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2495549','lexi-content-ref-17021358','lexi-content-ref-1736764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2495549','lexi-content-ref-17021358','lexi-content-ref-1736764'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021358'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphisms (eg, CYP450 2E1 and N-acetyltransferase 2 (NAT2) [ie, slow acetylation rate]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12668988','lexi-content-ref-30509962','lexi-content-ref-16770646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12668988','lexi-content-ref-30509962','lexi-content-ref-16770646'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isoniazid is associated with <b>peripheral neuropathy</b>, <b>paresthesia</b>, and sensory impairment, which have led to treatment disruptions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13080603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13080603'])">Ref</a></span>). Peripheral neuropathy is the most common neurologic effect; often reversible within a few months, especially following drug discontinuation and pyridoxine (vitamin B<sub>6</sub>) supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26440850','lexi-content-ref-6269259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26440850','lexi-content-ref-6269259'])">Ref</a></span>). Other neurologic effects may take longer to achieve complete recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26440850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26440850'])">Ref</a></span>). Preemptive pyridoxine supplementation is recommended in individuals at risk for development of peripheral neuropathies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>). Other neurologic effects that have been reported include <b>seizures</b>, <b>optic neuritis</b>, and <b>encephalopathy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25859682','lexi-content-ref-2152443','lexi-content-ref-11858381','lexi-content-ref-3115809','lexi-content-ref-384871','lexi-content-ref-31929489','lexi-content-ref-10708202','lexi-content-ref-32462048','lexi-content-ref-30173204','lexi-content-ref-18610679','lexi-content-ref-24492693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25859682','lexi-content-ref-2152443','lexi-content-ref-11858381','lexi-content-ref-3115809','lexi-content-ref-384871','lexi-content-ref-31929489','lexi-content-ref-10708202','lexi-content-ref-32462048','lexi-content-ref-30173204','lexi-content-ref-18610679','lexi-content-ref-24492693'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; peripheral neuropathy is thought to be due to a vitamin B<sub>6</sub> deficiency or competitive inhibition of vitamin B<sub>6</sub> action mediated by the formation of pyridoxal isonicotinyl hydrazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13189058','lexi-content-ref-6269259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13189058','lexi-content-ref-6269259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peripheral neuropathy often occurs after prolonged therapy (several months); however, cases as early as 10 days have been reported. Plasma levels of pyridoxal phosphate (active vitamin B<sub>6</sub>) are significantly reduced after 7 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29579435','lexi-content-ref-15139457','lexi-content-ref-22574487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29579435','lexi-content-ref-15139457','lexi-content-ref-22574487'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (peripheral neuropathy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13189058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13189058'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-6269259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-6269259'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-24176943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-24176943'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nutritional deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-677075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-677075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Slow acetylation rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13180863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13180863'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pregnant or breastfeeding females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F184746"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hepatic: Increased serum transaminases (increased serum alanine aminotransferase, increased serum aspartate aminotransferase; mild and transient: 10% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis (Bondalapati 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash (Ye 2017), morbilliform rash, purpuric rash (Duncan 1964), skin rash (exfoliative dermatitis [Rosin 1982]), toxic epidermal necrolysis (Lehloenya 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Poon 2020), hyperglycemia (Ganguly 2018), metabolic acidosis (Romero 1998), pellagra (Kabengele 2021), pyridoxine deficiency (Reeves 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Epigastric discomfort, nausea, pancreatitis (Mattioni 2012), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Mehrotra 1973), anemia (aplastic anemia, hemolytic anemia, sideroblastic anemia [Piso 2011]), eosinophilia, immune thrombocytopenia (Kuwabara 2021), lymphadenopathy, pure red cell aplasia (Hoffman 1983), thrombocytopenia (Lee 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Bilirubinuria, hepatitis (Chalasani 2021), hepatotoxicity (Chalasani 2021), hyperbilirubinemia (Chalasani 2021), jaundice (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Lehloenya 2015; Ye 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Low 2019), memory impairment, paresthesia, peripheral neuropathy (Arsalan 2015), seizure (Tsubouchi 2014), toxic psychosis (Alao 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Cerqueira 2020), rheumatism (Good 1970)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic atrophy (Sutton 1955), optic neuritis (Low 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Dasta 1979)</p></div>
<div class="block coi drugH1Div" id="F184763"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to isoniazid or any component of the formulation, including drug-induced hepatitis; acute liver disease; previous history of hepatic injury during isoniazid therapy; previous severe adverse reaction (drug fever, chills, arthritis) to isoniazid</p></div>
<div class="block war drugH1Div" id="F184743"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Multidrug regimens should be utilized for the treatment of tuberculosis (TB) disease (active TB) to prevent the emergence of drug resistance.</p></div>
<div class="block foc drugH1Div" id="F184755"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F184739"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F184766"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isoniazid Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $35.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Isoniazid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.86 - $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isoniazid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.31 - $1.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867268"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isotamine: 50 mg/5 mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isotamine: 100 mg [DSC], 300 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 300 mg</p></div>
<div class="block exp drugH1Div" id="F184761"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (50 mg/5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>10 mg/mL Oral Suspension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 10 mg/mL oral suspension may be made with tablets, purified water, and sorbitol. Crush ten 100 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of purified water and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 100 mL (do not use sugar-based solutions). Label "shake well" and "refrigerate". Stable for 21 days refrigerated.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613091"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer on an empty stomach (1 hour before or 2 hours after meals with water); if unable to swallow tablets, may crush tablet and mix in a soft food or liquid, or starch-based pudding (commercial chocolate pudding) and administer as a slurry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29363561','lexi-content-ref-17638210','lexi-content-ref-25580725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29363561','lexi-content-ref-17638210','lexi-content-ref-25580725'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IM: May be administered IM in patients who are unable to either take or absorb oral therapy.</p></div>
<div class="block adm drugH1Div" id="F803140"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Do not administer with food (bioavailability is decreased).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intramuscular:</b> IM injection may be used for patients who are unable to either take or absorb oral therapy. Inject deep IM into a large muscle mass.</p></div>
<div class="block sts drugH1Div" id="F184778"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Isoniazid injection may crystallize at low temperatures. If this occurs, warm the vial to room temperature before use to redissolve the crystals.</p></div>
<div class="block usep drugH1Div" id="F53567406"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of susceptible active tuberculosis (eg, <i>Mycobacterium tuberculosis</i>) infections in combination with other agents (FDA approved in children and adults); treatment of latent tuberculosis infection (LTBI) caused by <i>M. tuberculosis</i> (also referred to as prophylaxis or preventive therapy) (FDA approved in infants, children, and adults); has also been used for treatment of pulmonary nontuberculous mycobacterial infections.</p></div>
<div class="block mst drugH1Div" id="F3271336"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hydra [Japan] may be confused with Hydrea brand name for hydroxyurea [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F184818"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2E1 (moderate), CYP3A4 (weak); <b>Induces</b> CYP2E1 (weak)</p></div>
<div class="block dri drugH1Div" id="F184748"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Isoniazid may enhance the hepatotoxic effect of Acetaminophen. Isoniazid may increase the metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hepatotoxic effect of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the hepatotoxic effect of Isoniazid. Isoniazid may increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorzoxazone: Isoniazid may increase the serum concentration of Chlorzoxazone. Isoniazid may decrease the serum concentration of Chlorzoxazone. Specifically, it may decrease chlorzoxazone concentrations below baseline after isoniazid discontinuation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2E1 Inhibitors (Strong): May increase the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: May enhance the adverse/toxic effect of Isoniazid. Dolutegravir may increase the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethionamide: Isoniazid may increase the serum concentration of Ethionamide. Ethionamide may increase the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Isoniazid may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic).  Management: Avoid use of isoniazid from 2 weeks before and during treatment with ketoconazole when possible. If potential benefits outweigh the risks, monitor closely for reduced clinical response to ketoconazole and adjust the ketoconazole dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Isoniazid may diminish the therapeutic effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Isoniazid may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Isoniazid may increase the metabolism of Methoxyflurane. Specifically, this increased metabolism may lead to increased production of nephrotoxic metabolites. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Isoniazid may enhance the hepatotoxic effect of Propacetamol. Isoniazid may increase the metabolism of Propacetamol. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: Isoniazid may increase the serum concentration of Prothionamide. Prothionamide may increase the serum concentration of Isoniazid.  Management: Reduce the prothionamide dose by half (do not exceed 500 mg per day in adults) if combined with isoniazid. Additionally, monitor for increased isoniazid toxicities and ensure pyridoxine supplementation is provided if these drugs are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: Isoniazid may enhance the hepatotoxic effect of RifAMPin. RifAMPin may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the adverse/toxic effect of Isoniazid. Specifically, there is an increased risk for hypertension.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Isoniazid may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F184779"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Administration with food significantly reduces bioavailability. Management: Avoid administration with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid may decrease folic acid absorption and alters pyridoxine metabolism. Management: Increase dietary intake of folate, niacin, and magnesium.</p>
<p style="text-indent:-2em;margin-left:2em;">Tyramine-containing food: Isoniazid has weak monoamine oxidase inhibiting activity and may potentially inhibit tyramine metabolism. Several case reports of mild reactions (flushing, palpitations, headache, mild increase in blood pressure, diaphoresis) after ingestion of certain types of cheese or red wine, have been reported (Self 1999; Toutoungi, 1985). Management: Manufacturer’s labeling recommends avoiding tyramine-containing foods (eg, aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). However, the clinical relevance of the tyramine reaction for the vast majority of patients receiving isoniazid has been questioned due to isoniazid’s weak MAO inhibition and the relatively few published case reports of the interaction. Although not fully investigated, it has been proposed that the reaction has a genetic component and may only be significant in poor or intermediate acetylators since isoniazid is primarily inactivated by acetylation (DiMartini 1995; Toutoungi 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Histamine-containing food: Isoniazid may also inhibit diamine oxidase resulting in headache, sweating, palpitations, flushing, diarrhea, itching, wheezing, dyspnea or hypotension to histamine-containing foods (eg, skipjack, tuna, saury, other tropical fish). Management: Manufacturer’s labeling recommends avoiding histamine-containing foods; corticosteroids and antihistamines may be administered if histamine intoxication occurs (Miki 2005).</p></div>
<div class="block dic drugH1Div" id="F184769"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not take with food; avoid tyramine- and/or histamine-containing foods. Increase dietary intake of folate, niacin, magnesium.</p></div>
<div class="block pri drugH1Div" id="F184767"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Isoniazid crosses the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020) as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risks of untreated TB, isoniazid is recommended as part of the initial treatment regimen of drug-susceptible TB disease when the probability of maternal disease is moderate to high. Isoniazid is associated with an increased risk of severe maternal hepatotoxicity which may require temporary drug withdrawal in pregnant and postpartum patients (Beck-Friis 2020; Gupta 2019); monthly monitoring of transaminases (ALT/AST) is recommended (HHS [OI adult 2020]). Pregnancy may increase the risk of isoniazid-associated peripheral neurotoxicity in the mother; pyridoxine supplementation is recommended in pregnant patients during treatment (ATS/CDC/IDSA [Nahid 2016]; HHS [OI adult 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of TB infection (latent TB) (also known as prophylaxis or preventive therapy) with isoniazid is recommended for pregnant patients with HIV coinfection who are close household contacts of persons with TB disease (HHS [OI adult 2020]; WHO 2020). Treatment of TB infection can be delayed until after delivery in some cases, considering the risk of progression to active disease (HHS [OI adult 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of isoniazid in a clinically significant way; dose adjustment is not needed in pregnant patients (Abdelwahab 2020).</p></div>
<div class="block mopp drugH1Div" id="F53567383"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and periodic (more frequently in patients with higher risk for hepatitis or with previous abnormal results) liver function tests (ALT and AST); monitor for peripheral neuropathy and prodromal signs of hepatitis.</p></div>
<div class="block pha drugH1Div" id="F184742"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms.</p></div>
<div class="block phk drugH1Div" id="F184762"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Isoniazid is primarily metabolized by acetylation and dehydrazination. Rate of acetylation is genetically determined. Approximately 50% of Black and White patients are “slow acetylators” and the rest are “rapid acetylators.” Populations in which there is a high prevalence of “rapid acetylators” include Inuit patients (including native peoples from Alaska and Canada), East Asian patients, and patients from certain areas within Southeast Asia (eg, Thailand) (Clark 1985; Sabbagh 2011; manufacturer's labeling). Acetylation rate does not significantly alter the effectiveness, but slow acetylation may lead to higher blood levels and possibly an increase in adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Absorption: Oral, IM: Rapid and complete; food reduces rate and extent of absorption</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: All body tissues and fluids including CSF</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 10% to 15%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to acetylisoniazid with decay rate determined genetically by acetylation phenotype; undergoes further hydrolysis to isonicotinic acid and acetylhydrazine</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life: May be prolonged in patients with impaired hepatic function or severe renal impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Fast acetylators: 30 to 100 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Slow acetylators: 2 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75% to 95% as unchanged drug and metabolites); small amounts excreted in feces and saliva</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F184770"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Isoniac | Isoniazida lafedar | Nicotibina</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Inh | Isonex | Isotab | Servizid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nicotibine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Isonid | Rimicid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Farmanguinhos isoniazida | Furp isoniazida | Isoniazida laqfa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gotbison | Isoniazida | Nidrazyl | Nydrazid | Solonex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nidrazid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Inh-burgthal | Isozid | Tebesium-s</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isoniazida | Isonidom</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Isoniazida | Nicetal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Inh | Isoniazide | Isozid | Tubilysin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Inh | Isocid | Isoniazide | T.B.Zide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nicotubin | Tubilysin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Isoniazid dc | Rimifon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dianicotyl | Isonid | Isozid | Nicozide | Rimifon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Inafan | Inah</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Isonicid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Inh | Inh-ciba | Isonex | Isoniazide</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nicotibine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Inazid | Isoniazide</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alsonex | Isonex | Lup inh | Solonex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nicizina | Nicozid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diazid | Hycozid | Hydra | Hydronsan | Iscotin | Isoniazid sankei | Isoniazid taisho | Isoniazid taiyo | Niazid | Niplen | Sumifon | Tuberon | Vivoniplen</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bitub | Isozide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aina yuyu | Diazid | Inah | Korus isonicotinic acid hydrazide | Nydrazid | Yuhan-zid | Yuhanzid | Zisonin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isozid | Izoniazida arena | Rimicid | Solonex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nicotibine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Isozid | Methazid | Rimicid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Rimifon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Isodotbal | Isoniazida | Valifol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Inh | Isonize</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Isoniamec</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isoniazide</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isoniazid naf krageroe | Isozid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Isoniazida | Isoniazida cipa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biogenerics isoniazid | Curazid | Dli-isoniazid | Dongin | Isonex | Isoniazid Pacific | Isonic | Isonid | Isonix | Niazid | Nicetal | Zidrid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Isozide | Izid | Nydrazide</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Isoniazidum | Isonid | Isozid | Nidrazid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Laniazid | Nydrazid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hidrazida | Isoniazida | Nicotibine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Isoniazida | Izoniazida Atb</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fenazid | Isoniasid | Isozid | Methazid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Isoniazide | Pdp isoniazid | Pms-isoniazid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tibinide</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Isonize</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Isozid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nidrazid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Antimic | Antituban | Inh | Iso | Isonic | Isophiha | Nydrazid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Isoniazide | Niazid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">I.n.h.</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Duracrin | Hydrazin | Inah | Isonicotinic | Isonicotinyl Hydrazine | Isonin | Lunging | Nydrazid | Rimifon | Tubanin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agozid | Isoniazide</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Nydrazid</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Meko inh</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Be-tabs isoniazid | I N H | Isoniazid adco | Isoniazid pharma q | Lennon isoniazid | Norstan-isoniazid | Winthrop Isoniazid</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">I.n.h.</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31844002">
<a name="31844002"></a>Abdelwahab MT, Leisegang R, Dooley KE, et al. Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. <i>Antimicrob Agents Chemother</i>. 2020;64(3):e01978-19. doi:10.1128/AAC.01978-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31844002/pubmed" id="31844002" target="_blank">31844002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12968844">
<a name="12968844"></a>Ahn C, Oh KH, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin<i>. Perit Dial Int.</i> 2003;23(4):362-367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12968844/pubmed" id="12968844" target="_blank">12968844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6650978">
<a name="6650978"></a>Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. <i>Am Rev Respir Dis</i>. 1983;128(6):1048-1050. doi:10.1164/arrd.1983.128.6.1048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6650978/pubmed" id="6650978" target="_blank">6650978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25859682">
<a name="25859682"></a>Aiwale AS, Patel UA, Barvaliya MJ, Jha PR, Tripathi C. Isoniazid induced convulsions at therapeutic dose in an alcoholic and smoker patient. <i>Curr Drug Saf</i>. 2015;10(1):94-95. doi:10.2174/1574886309666140930151343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/25859682/pubmed" id="25859682" target="_blank">25859682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9762376">
<a name="9762376"></a>Alao AO, Yolles JC. Isoniazid-induced psychosis. <i>Ann Pharmacother</i>. 1998;32(9):889-891. doi:10.1345/aph.17377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/9762376/pubmed" id="9762376" target="_blank">9762376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1728006">
<a name="1728006"></a>American Academy of Pediatrics, Committee on Infectious Diseases. Chemotherapy for Tuberculosis in Infants and Children. <i>Pediatrics</i>. 1992;89(1):161-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/1728006/pubmed" id="1728006" target="_blank">1728006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26440850">
<a name="26440850"></a>Arsalan R, Sabzwari S. Isoniazid induced motor-dominant neuropathy. <i>J Pak Med Assoc</i>. 2015;65(10):1131-1133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/26440850/pubmed" id="26440850" target="_blank">26440850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7701468">
<a name="7701468"></a>Askgaard DS, Wilcke T, Dossing M. Hepatotoxicity Caused by the Combined Action of Isoniazid and Rifampicin. <i>Thorax</i>. 1995;50(2):213-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/7701468/pubmed" id="7701468" target="_blank">7701468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32592906">
<a name="32592906"></a>Beck-Friis J, Studahl M, Yilmaz A, Andersson R, Lönnermark E. Increased risk of hepatotoxicity and temporary drug withdrawal during treatment of active tuberculosis in pregnant women. <i>Int J Infect Dis</i>. 2020;98:138-143. doi:10.1016/j.ijid.2020.06.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/32592906/pubmed" id="32592906" target="_blank">32592906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berlin.1">
<a name="Berlin.1"></a>Berlin CM Jr, Lee C. Isoniazid and acetylisoniazid disposition in human milk, saliva and plasma. Federation of American Societies for Experimental Biology 63rd Annual Meeting, Dallas, Texas, April 1-10, 1979. Abstracts of papers. Part I. <i>Fed Proc</i>. 1979;38(3, pt 1):426.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13189058">
<a name="13189058"></a>Biehl JP, Nimitz HJ. Studies on the use of high dose of isoniazid. I. Toxicity studies. <i>Am Rev Tuberc</i>. 1954;70(3):430-441. doi:10.1164/art.1954.70.3.430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/13189058/pubmed" id="13189058" target="_blank">13189058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7662061">
<a name="7662061"></a>Blowey DL, Johnson D, Verjee Z. Isoniazid-Associated Rhabdomyolysis. <i>Am J Emerg Med</i>. 1995;13(5):543-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/7662061/pubmed" id="7662061" target="_blank">7662061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25302231">
<a name="25302231"></a>Bondalapati S, V DR, Rampure D, S RR. Isoniazid induced cutaneous leukocytoclastic vasculitis in extra pulmonary tuberculosis (Pott's spine): a case report. <i>J Clin Diagn Res</i>. 2014;8(8):MD03-MD5. doi:10.7860/JCDR/2014/9000.4688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/25302231/pubmed" id="25302231" target="_blank">25302231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29953429">
<a name="29953429"></a>Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection. <i>MMWR Morb Mortal Wkly Rep</i>. 2018;67(25):723-726. doi:10.15585/mmwr.mm6725a5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29953429/pubmed" id="29953429" target="_blank">29953429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2221419">
<a name="2221419"></a>Bredemann JA, Krechel SW, Eggers GW Jr. Treatment of Refractory Seizures in Massive Isoniazid Overdose. <i>Anesth Analg</i>. 1990;71(5):554-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2221419/pubmed" id="2221419" target="_blank">2221419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2152443">
<a name="2152443"></a>Brent J, Vo N, Kulig K, et al. Reversal of prolonged isoniazid-induced coma by pyridoxine. <i>Arch Intern Med</i>. 1990;150(8):1751-1753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2152443/pubmed" id="2152443" target="_blank">2152443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5009799">
<a name="5009799"></a>Brown CV. Acute Isoniazid Poisoning. <i>Am Rev Respir Dis</i>. 1972;105(2):206-216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/5009799/pubmed" id="5009799" target="_blank">5009799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35202353">
<a name="35202353"></a>Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. <i>MMWR Morb Mortal Wkly Rep</i>. 2022;71(8):285-289. doi:10.15585/mmwr.mm7108a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/35202353/pubmed" id="35202353" target="_blank">35202353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12904741">
<a name="12904741"></a>Centers for Disease Control and Prevention (CDC) and American Thoracic Society. Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003. <i>MMWR Morb Mortal Wkly Rep</i>. 2003;52(31):735-739. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12904741/pubmed" id="12904741" target="_blank">12904741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20203555">
<a name="20203555"></a>Centers for Disease Control and Prevention (CDC). Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection -- United States, 2004-08. <i>MMWR Morb Mortal Wkly Rep</i>. 2010;59(8):224-229. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/20203555/pubmed" id="20203555" target="_blank">20203555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32313752">
<a name="32313752"></a>Cerqueira A, Seco T, Paiva D, Martins H, Cotter J. Isoniazid-induced lupus: when the cure can be lethal. <i>Cureus</i>. 2020;12(3):e7311. doi:10.7759/cureus.7311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/32313752/pubmed" id="32313752" target="_blank">32313752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27103355">
<a name="27103355"></a>Chaitanya V, Sangeetha B, Reddy MH, et al. Isoniazid cerebellitis in a peritoneal dialysis patient. <i>Nephrology (Carlton)</i>. 2016;21(5):442. doi:10.1111/nep.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/27103355/pubmed" id="27103355" target="_blank">27103355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8324207">
<a name="8324207"></a>Cheung WC, Lo CY, Lo WK, Ip M, Cheng IK. Isoniazid induced encephalopathy in dialysis patients. <i>Tuber Lung Dis.</i> 1993;74(2):136-139. doi:10.1016/0962-8479(93)90042-V<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/8324207/pubmed" id="8324207" target="_blank">8324207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29579435">
<a name="29579435"></a>Choudhary CR, Kumari J, Advani M. Isoniazid induced early-onset of motor dominant neuropathy and treatment with high dose of pyridoxine. <i>Indian J Tuberc</i>. 2018;65(2):175-176. doi:10.1016/j.ijtb.2017.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29579435/pubmed" id="29579435" target="_blank">29579435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11858381">
<a name="11858381"></a>Citak A, Kaya O, Uçsel R, Karaböcüoğlu M, Uzel N. Acute isoniazid neurotoxicity in childhood. <i>Turk J Pediatr</i>. 2002;44(1):54-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/11858381/pubmed" id="11858381" target="_blank">11858381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2859977">
<a name="2859977"></a>Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications. <i>Drugs</i>. 1985;29(4):342-375. doi:10.2165/00003495-198529040-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2859977/pubmed" id="2859977" target="_blank">2859977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28870161">
<a name="28870161"></a>Constantinescu SM, Buysschaert B, Haufroid V, Broly F, Jadoul M, Morelle J. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review. <i>BMC Nephrol</i>. 2017;18(1):282. doi:10.1186/s12882-017-0703-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/28870161/pubmed" id="28870161" target="_blank">28870161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29363561">
<a name="29363561"></a>Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. <i>Pediatrics</i>. 2018;141(2):e20172838. doi:10.1542/peds.2017-2838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29363561/pubmed" id="29363561" target="_blank">29363561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-421557">
<a name="421557"></a>Dasta JF, Prior JA, Kurzrok S. Isoniazid-induced fever. <i>Chest</i>. 1979;75(2):196-197. doi:10.1378/chest.75.2.196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/421557/pubmed" id="421557" target="_blank">421557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26730567">
<a name="26730567"></a>Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. <i>AIDS</i>. 2016;30(5):797-801. doi:10.1097/QAD.0000000000000985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/26730567/pubmed" id="26730567" target="_blank">26730567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8675973">
<a name="8675973"></a>DiMartini A. Isoniazid, Tricyclics and the “Cheese Reaction." <i>Int Clin Psychopharmacol</i>. 1995;10(3):197-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/8675973/pubmed" id="8675973" target="_blank">8675973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945300">
<a name="31945300"></a>Dooley KE, Miyahara S, von Groote-Bidlingmaier F, et al; A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial. <i>Am J Respir Crit Care Med</i>. 2020;201(11):1416–24. doi:10.1164/rccm.201910-1960OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31945300/pubmed" id="31945300" target="_blank">31945300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33951360">
<a name="33951360"></a>Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. <i>N Engl J Med</i>. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/33951360/pubmed" id="33951360" target="_blank">33951360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14114404">
<a name="14114404"></a>Duncan JT. Nonthrombopenic purpura resulting from sensitivity to isoniazid. <i>Am Rev Respir Dis</i>. 1964;89:103-104. doi:10.1164/arrd.1964.89.1.103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/14114404/pubmed" id="14114404" target="_blank">14114404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12539070">
<a name="12539070"></a>Fernández-Villar A, Sopeña B, Vázquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. <i>Clin Infect Dis</i>. 2003;36(3):293-298. doi:10.1086/345906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12539070/pubmed" id="12539070" target="_blank">12539070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2495549">
<a name="2495549"></a>Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. <i>Public Health Rep</i>. 1989;104(2):151-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2495549/pubmed" id="2495549" target="_blank">2495549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13678977">
<a name="13678977"></a>Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. <i>Lancet.</i> 2003;362(9387):887-899.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/13678977/pubmed" id="13678977" target="_blank">13678977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30598974">
<a name="30598974"></a>Ganguly RJ, Abraham RR, Prasad R, Rao BC. Hyperglycaemia induced by isoniazid preventive therapy. <i>J Family Med Prim Care</i>. 2018;7(5):1123-1125. doi:10.4103/jfmpc.jfmpc_197_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30598974/pubmed" id="30598974" target="_blank">30598974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30723406">
<a name="30723406"></a>Garessus EDG, Mielke H, Gundert-Remy U. Exposure of infants to isoniazid via breast milk after maternal drug intake of recommended doses is clinically insignificant irrespective of metaboliser status. A physiologically-based pharmacokinetic (PBPK) modelling approach to estimate drug exposure of infants via breast-feeding. <i>Front Pharmacol</i>. 2019;10:5. doi:10.3389/fphar.2019.00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30723406/pubmed" id="30723406" target="_blank">30723406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-954244">
<a name="954244"></a>Gold CH, Buchanan N, Tringham V, Viljoen M, Strickwold B, Moodley GP. Isoniazid pharmacokinetics in patients in chronic renal failure. <i>Clin Nephrol</i>. 1976;6(2):365-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/954244/pubmed" id="954244" target="_blank">954244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5311006">
<a name="5311006"></a>Good AE. Rheumatism and chemotherapy of tuberculosis. <i>Ann Intern Med</i>. 1970;72(5):752-753. doi:10.7326/0003-4819-72-5-752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/5311006/pubmed" id="5311006" target="_blank">5311006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577875">
<a name="31577875"></a>Gupta A, Montepiedra G, Aaron L, et al; IMPAACT P1078 TB APPRISE Study Team. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. <i>N Engl J Med</i>. 2019;381(14):1333-1346. doi:10.1056/NEJMoa1813060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31577875/pubmed" id="31577875" target="_blank">31577875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29995958">
<a name="29995958"></a>Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Med</i>. 2018;15(7):e1002591. doi:10.1371/journal.pmed.1002591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29995958/pubmed" id="29995958" target="_blank">29995958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9929528">
<a name="9929528"></a>Havlir DV, Barnes PF. Tuberculosis in Patients With Human Immunodeficiency Virus Infection. <i>N Engl J Med</i>. 1999;340(5):367-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/9929528/pubmed" id="9929528" target="_blank">9929528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(Suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31192819">
<a name="31192819"></a>Hill WC, Paruolo JB, Giovino AC. Prophylaxis for tuberculosis in pregnant women. <i>Clin Obstet Gynecol.</i> 2019;62(4):846-856. doi:10.1097/GRF.0000000000000465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31192819/pubmed" id="31192819" target="_blank">31192819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6869413">
<a name="6869413"></a>Hoffman R, McPhedran P, Benz EJ Jr, Duffy TP. Isoniazid-induced pure red cell aplasia. <i>Am J Med Sci</i>. 1983;286(1):2-9. doi:10.1097/00000441-198307000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6869413/pubmed" id="6869413" target="_blank">6869413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668988">
<a name="12668988"></a>Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. <i>Hepatology</i>. 2003;37(4):924-930. doi:10.1053/jhep.2003.50144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12668988/pubmed" id="12668988" target="_blank">12668988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13180863">
<a name="13180863"></a>Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. <i>Am Rev Tuberc</i>. 1954;70(2):266-273. doi:10.1164/art.1954.70.2.266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/13180863/pubmed" id="13180863" target="_blank">13180863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8350889">
<a name="8350889"></a>Iseman MD. Treatment of Multidrug-Resistant Tuberculosis. <i>N Engl J Med</i>. 1993;329(11):784-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/8350889/pubmed" id="8350889" target="_blank">8350889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isoniazid.1">
<a name="Isoniazid.1"></a>Isoniazid injection [prescribing information]. Princeton, NJ: Sandoz Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isoniazid.2">
<a name="Isoniazid.2"></a>Isoniazid oral solution [prescribing information]. Farmville, NC: CMP Pharma; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isoniazid.3">
<a name="Isoniazid.3"></a>Isoniazid tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3115809">
<a name="3115809"></a>Jimenez-Lucho VE, del Busto R, Odel J. Isoniazid and ethambutol as a cause of optic neuropathy. <i>Eur J Respir Dis</i>. 1987;71(1):42-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/3115809/pubmed" id="3115809" target="_blank">3115809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34422196">
<a name="34422196"></a>Kabengele C, M'hango H, Mweemba D, Malumani M. A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. <i>Pan Afr Med J</i>. 2021;39:73. doi:10.11604/pamj.2021.39.73.28072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/34422196/pubmed" id="34422196" target="_blank">34422196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-384871">
<a name="384871"></a>Karmon G, Savir H, Zevin D, Levi J. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. <i>Ann Ophthalmol</i>. 1979;11(7):1013-1017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/384871/pubmed" id="384871" target="_blank">384871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3732371">
<a name="3732371"></a>Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of Isoniazid: Influence of Age. <i>Eur J Clin Pharmacol</i>. 1986;30(3):335-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/3732371/pubmed" id="3732371" target="_blank">3732371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30509962">
<a name="30509962"></a>Khan S, Mandal RK, Elasbali AM, et al. Pharmacogenetic association between <i>NAT2</i> gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. <i>Biosci Rep</i>. 2019;39(1):BSR20180845. doi:10.1042/BSR20180845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30509962/pubmed" id="30509962" target="_blank">30509962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-666111">
<a name="666111"></a>Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. <i>Am Rev Respir Dis</i>. 1978;117(6):991-1001. doi:10.1164/arrd.1978.117.6.991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/666111/pubmed" id="666111" target="_blank">666111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34053983">
<a name="34053983"></a>Kuwabara G, Tazoe K, Imoto W, et al. Isoniazid-induced immune thrombocytopenia. <i>Intern Med</i>. 2021;60(22):3639-3643. doi:10.2169/internalmedicine.6520-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/34053983/pubmed" id="34053983" target="_blank">34053983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22466831">
<a name="22466831"></a>Lee EJ, Lee SH, Kim YE, et al. A case of isoniazid-induced thrombocytopenia: recovery with immunoglobulin therapy. <i>Intern Med</i>. 2012;51(7):745-748. doi:10.2169/internalmedicine.51.6296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22466831/pubmed" id="22466831" target="_blank">22466831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25653694">
<a name="25653694"></a>Lee JY, Seol YJ, Shin DW, et al. A case of the drug reaction with eosinophilia and systemic symptom (DRESS) following isoniazid treatment. <i>Tuberc Respir Dis (Seoul)</i>. 2015;78(1):27-30. doi:10.4046/trd.2015.78.1.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/25653694/pubmed" id="25653694" target="_blank">25653694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26142408">
<a name="26142408"></a>Lehloenya RJ, Muloiwa R, Dlamini S, Gantsho N, Todd G, Dheda K. Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. <i>J Antimicrob Chemother</i>. 2015;70(9):2648-2651. doi:10.1093/jac/dkv158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/26142408/pubmed" id="26142408" target="_blank">26142408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132339">
<a name="22132339"></a>Loto OM, Awowole I. Tuberculosis in pregnancy: a review. <i>J Pregnancy</i>. 2012;2012:379271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22132339/pubmed" id="22132339" target="_blank">22132339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31929489">
<a name="31929489"></a>Low JM, Wong KW. Isoniazid-induced encephalopathy in an end-stage renal disease patient - a case report and literature review. <i>Med J Malaysia.</i> 2019;74(6):553-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31929489/pubmed" id="31929489" target="_blank">31929489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13080603">
<a name="13080603"></a>Lubing HN. Peripheral neuropathy in tuberculosis patients treated with isoniazid. <i>Am Rev Tuberc</i>. 1953;68(3):458-461. doi:10.1164/art.1953.68.3.458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/13080603/pubmed" id="13080603" target="_blank">13080603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10228130">
<a name="10228130"></a>Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. <i>Am J Respir Crit Care Med.</i> 1999;159(5 Pt 1):1580-1584. doi:10.1164/ajrccm.159.5.9810034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/10228130/pubmed" id="10228130" target="_blank">10228130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10708202">
<a name="10708202"></a>Martinjak-Dvorsek I, Gorjup V, Horvat M, Noc M. Acute isoniazid neurotoxicity during preventive therapy. <i>Crit Care Med</i>. 2000;28(2):567-568. doi:10.1097/00003246-200002000-00047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/10708202/pubmed" id="10708202" target="_blank">10708202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22942202">
<a name="22942202"></a>Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. <i>Clin Infect Dis</i>. 2012;55(11):1532-1549. doi:10.1093/cid/cis732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22942202/pubmed" id="22942202" target="_blank">22942202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22572141">
<a name="22572141"></a>Mattioni S, Zamy M, Mechai F, et al. Isoniazid-induced recurrent pancreatitis. <i>JOP</i>. 2012;13(3):314-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22572141/pubmed" id="22572141" target="_blank">22572141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4746240">
<a name="4746240"></a>Mehrotra TN, Gupta SK. Agranulocytosis following isoniazid. Report of a case. <i>Indian J Med Sci</i>. 1973;27(5):392-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/4746240/pubmed" id="4746240" target="_blank">4746240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16357449">
<a name="16357449"></a>Miki M, Ishikawa T, Okayama H. An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward. <i>Intern Med</i>. 2005;44(11):1133-1136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/16357449/pubmed" id="16357449" target="_blank">16357449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24176943">
<a name="24176943"></a>Naidoo A, Naidoo K, Yende-Zuma N, et al. Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. <i>Antivir Ther</i>. 2014;19(2):161-169. doi:10.3851/IMP2701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/24176943/pubmed" id="24176943" target="_blank">24176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32462048">
<a name="32462048"></a>Navalkele B, Bueno Rios MX, Wofford JD, Kumar V, Webb RM. Seizures in an immunocompetent adult from treatment of latent tuberculosis infection: is isoniazid to blame? <i>Open Forum Infect Dis</i>. 2020;7(5):ofaa144. doi:10.1093/ofid/ofaa144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/32462048/pubmed" id="32462048" target="_blank">32462048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Noble.1">
<a name="Noble.1"></a>Noble A. Antituberculous Therapy and Acute Liver Failure. <i>Lancet</i>. 1995;345(8953):867.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6007094">
<a name="6007094"></a>O'Sullivan DC. Isoniazid jaundice during the treatment of genitourinary tuberculosis. <i>Tubercle</i>. 1966;47(2):221-4. doi:10.1016/s0041-3879(66)80039-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6007094/pubmed" id="6007094" target="_blank">6007094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17638210">
<a name="17638210"></a>Peloquin CA, Durbin D, Childs J, Sterling TR, Weiner M. Stability of antituberculosis drugs mixed in food. <i>Clin Infect Dis</i>. 2007;45(4):521.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/17638210/pubmed" id="17638210" target="_blank">17638210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36147124">
<a name="36147124"></a>Permatasari A, Soegiarto G. Management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a female Indonesian with pulmonary tuberculosis: a rare case report. <i>Ann Med Surg (Lond)</i>. 2022;81:104512. doi:10.1016/j.amsu.2022.104512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/36147124/pubmed" id="36147124" target="_blank">36147124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22184524">
<a name="22184524"></a>Piso RJ, Kriz K, Desax MC. Severe isoniazid related sideroblastic anemia. <i>Hematol Rep</i>. 2011;3(1):e2. doi:10.4081/hr.2011.e2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22184524/pubmed" id="22184524" target="_blank">22184524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33109161">
<a name="33109161"></a>Poon SWY, Siu KK, Tsang AMC. Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature. <i>BMC Endocr Disord</i>. 2020;20(1):160. doi:10.1186/s12902-020-00639-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/33109161/pubmed" id="33109161" target="_blank">33109161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention. <i>MMWR Recomm Rep</i>. 1998;47(RR-20):1-58.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8053617">
<a name="8053617"></a>Rabassa AA, Trey G, Shukla U, et al. Isoniazid-Induced Acute Pancreatitis. <i>Ann Intern Med</i>. 1994;121(6):433-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/8053617/pubmed" id="8053617" target="_blank">8053617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30173204">
<a name="30173204"></a>Rana P, Roy V, Ahmad J. Drug-induced optic neuropathy in a case of extensively drug-resistant pulmonary tuberculosis. <i>J Basic Clin Physiol Pharmacol</i>. 2018;30(1):139-140. doi:10.1515/jbcpp-2018-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30173204/pubmed" id="30173204" target="_blank">30173204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15546832">
<a name="15546832"></a>Reeves RR, Liberto V. Confusion associated with isoniazid-induced pyridoxine deficiency. <i>Psychosomatics</i>. 2004;45(6):537-538. doi:10.1176/appi.psy.45.6.537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/15546832/pubmed" id="15546832" target="_blank">15546832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14372127">
<a name="14372127"></a>Ricci G, Copaitich T. Elimination of orally administered isoniazid in human milk. <i>Rass Clin Ter</i>. 1954;53(4):209-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/14372127/pubmed" id="14372127" target="_blank">14372127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9490997">
<a name="9490997"></a>Romero JA, Kuczler FJ Jr. Isoniazid overdose: recognition and management. <i>Am Fam Physician</i>. 1998;57(4):749-752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/9490997/pubmed" id="9490997" target="_blank">9490997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6459647">
<a name="6459647"></a>Rosin MA, King LE Jr. Isoniazid-induced exfoliative dermatitis. <i>South Med J</i>. 1982;75(1):81. doi:10.1097/00007611-198201000-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6459647/pubmed" id="6459647" target="_blank">6459647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21494681">
<a name="21494681"></a>Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. <i>PLoS One</i>. 2011;6(4):e18507. doi:10.1371/journal.pone.0018507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/21494681/pubmed" id="21494681" target="_blank">21494681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17021358">
<a name="17021358"></a>Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. <i>Am J Respir Crit Care Med</i>. 2006;174(8):935-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/17021358/pubmed" id="17021358" target="_blank">17021358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7780090">
<a name="7780090"></a>Sauret J, Hernández-Flix S, Castro E, Hernández L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. <i>Tuber Lung Dis</i>. 1995;76(2):104-108. doi:10.1016/0962-8479(95)90550-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/7780090/pubmed" id="7780090" target="_blank">7780090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scharman.1">
<a name="Scharman.1"></a>Scharman EJ, Rosencrane JG. Isoniazid Toxicity: A Survey of Pyridoxine Availability. <i>Am J Emerg Med</i>. 1994;12(3):386-388.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schluger.1">
<a name="Schluger.1"></a>Schluger NW, Heysell SK, Friedland G. Treatment of drug-resistant pulmonary tuberculosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10334118">
<a name="10334118"></a>Self TH, Chrisman CR, Baciewicz AM, et al. Isoniazid Drug and Food Interactions. <i>Am J Med Sci</i>. 1999;317(5):304-311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/10334118/pubmed" id="10334118" target="_blank">10334118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sharieff.1">
<a name="Sharieff.1"></a>Sharieff G, Shad JA. Early Recognition of Isoniazid Overdose. <i>Hosp Physician</i>. 1995;31(5):22-22.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776936">
<a name="29776936"></a>Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. <i>BMJ Case Rep.</i> 2018;2018:bcr2017223187. doi:10.1136/bcr-2017-223187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/29776936/pubmed" id="29776936" target="_blank">29776936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1136966">
<a name="1136966"></a>Sievers ML, Herrier RN. Treatment of Acute Isoniazid Toxicity. <i>Am J Hosp Pharm</i>. 1975;32(2):202-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/1136966/pubmed" id="1136966" target="_blank">1136966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18093257">
<a name="18093257"></a>Singh N, Golani A, Patel Z, Maitra A. Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. <i>Br J Clin Pharmacol</i>. 2008;65(3):418-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/18093257/pubmed" id="18093257" target="_blank">18093257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1736764">
<a name="1736764"></a>Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. <i>Am Rev Respir Dis</i>. 1992;145(2 pt 1):494-497. doi:10.1164/ajrccm/145.2_Pt_1.494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/1736764/pubmed" id="1736764" target="_blank">1736764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6269259">
<a name="6269259"></a>Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. <i>Tubercle</i>. 1980;61(4):191-196. doi:10.1016/0041-3879(80)90038-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6269259/pubmed" id="6269259" target="_blank">6269259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3287309">
<a name="3287309"></a>Starke JR. Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children. <i>Pediatr Clin North Am</i>. 1988;35(3):441-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/3287309/pubmed" id="3287309" target="_blank">3287309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2124671">
<a name="2124671"></a>Starke JR. Multidrug Therapy for Tuberculosis in Children. <i>Pediatr Infect Dis J</i>. 1990;9(11):785-793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2124671/pubmed" id="2124671" target="_blank">2124671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32053584">
<a name="32053584"></a>Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>MMWR Recomm Rep</i>. 2020;69(1):1-11. doi:10.15585/mmwr.rr6901a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/32053584/pubmed" id="32053584" target="_blank">32053584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22150035">
<a name="22150035"></a>Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. <i>N Engl J Med</i>. 2011;365(23):2155-2166. doi:10.1056/NEJMoa1104875<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22150035/pubmed" id="22150035" target="_blank">22150035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27243774">
<a name="27243774"></a>Sterling TR, Scott NA, Miro JM, et al; Tuberculosis Trials Consortium; the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259). Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. <i>AIDS</i>. 2016;30(10):1607-1615. doi:10.1097/QAD.0000000000001098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/27243774/pubmed" id="27243774" target="_blank">27243774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14354959">
<a name="14354959"></a>Sutton PH, Beattie PH. Optic atrophy after administration of isoniazid with P.A.S. <i>Lancet</i>. 1955;268(6865):650-651. doi:10.1016/s0140-6736(55)90321-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/14354959/pubmed" id="14354959" target="_blank">14354959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18610679">
<a name="18610679"></a>Tajender V, Saluja J. INH induced status epilepticus: response to pyridoxine. <i>Indian J Chest Dis Allied Sci</i>. 2006;48(3):205-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/18610679/pubmed" id="18610679" target="_blank">18610679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2863660">
<a name="2863660"></a>Toutoungi M, Carroll RL, Enrico JF, et al. Cheese, Wine, and Isoniazid. <i>Lancet</i>. 1985;2(8456):671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2863660/pubmed" id="2863660" target="_blank">2863660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492693">
<a name="24492693"></a>Tsubouchi K, Ikematsu Y, Hashisako M, Harada E, Miyagi H, Fujisawa N. Convulsive seizures with a therapeutic dose of isoniazid. <i>Intern Med</i>. 2014;53(3):239-242. doi:10.2169/internalmedicine.53.1303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/24492693/pubmed" id="24492693" target="_blank">24492693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Accessed June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>. Updated December 9, 2019. Accessed March 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6834890">
<a name="6834890"></a>Van Scoy RE, Wilkowske CJ. Antituberculous Agents: Isoniazid, Rifampin, Streptomycin, Ethambutol, and Pyrazinamide. <i>Mayo Clin Proc</i>. 1983; 58(4):233-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6834890/pubmed" id="6834890" target="_blank">6834890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25580725">
<a name="25580725"></a>Villarino ME, Scott NA, Weis SE, et al; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. <i>JAMA Pediatr</i>. 2015;169(3):247-255. doi:10.1001/jamapediatrics.2014.3158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/25580725/pubmed" id="25580725" target="_blank">25580725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-677075">
<a name="677075"></a>Vir SC, Love AH. Vitamin B6 status of the hospitalized aged. <i>Am J Clin Nutr</i>. 1978;31(8):1383-1391. doi:10.1093/ajcn/31.8.1383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/677075/pubmed" id="677075" target="_blank">677075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15139457">
<a name="15139457"></a>Visser ME, Texeira-Swiegelaar C, Maartens G. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. <i>Int J Tuberc Lung Dis</i>. 2004;8(2):260-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/15139457/pubmed" id="15139457" target="_blank">15139457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16770646">
<a name="16770646"></a>Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. <i>Eur J Clin Pharmacol</i>. 2006;62(6):423-429. doi:10.1007/s00228-006-0111-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/16770646/pubmed" id="16770646" target="_blank">16770646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30698688">
<a name="30698688"></a>Walsh KF, Vilbrun SC, Souroutzidis A, et al. Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti. <i>Clin Infect Dis</i>. 2019;69(4):717-719. doi:10.1093/cid/ciz039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30698688/pubmed" id="30698688" target="_blank">30698688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7265398">
<a name="7265398"></a>Wason S, LaCoutore PG, Lovejoy FH Jr. Single High-Dose Pyridoxine Treatment for Isoniazid Overdose. <i>JAMA</i>. 1981;246(10):1102-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/7265398/pubmed" id="7265398" target="_blank">7265398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-391461">
<a name="391461"></a>Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. <i>Clin Pharmacokinet.</i> 1979;4(6):401-422. doi:10.2165/00003088-197904060-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/391461/pubmed" id="391461" target="_blank">391461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30277688">
<a name="30277688"></a>World Health Organization (WHO). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: World Health Organization; 2018. <a href="http://www.ncbi.nlm.nih.gov/books/NBK531235/" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK531235/</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/30277688/pubmed" id="30277688" target="_blank">30277688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). <i>Treatment of Tuberculosis Guidelines</i>. 4th ed. Geneva, Switzerland: WHO Press; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). <i>WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: module 1: prevention [Internet]</i>. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.4">
<a name="WHO.4"></a>World Health Organization (WHO). <i>WHO consolidated guidelines on drug-resistant tuberculosis treatment.</i> World Health Organization; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27373553">
<a name="27373553"></a>Ye YM, Hur GY, Kim SH, et al. Drug-specific CD4<sup>+</sup> T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. <i>Br J Dermatol</i>. 2017;176(2):378-386. doi:10.1111/bjd.14839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/27373553/pubmed" id="27373553" target="_blank">27373553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1740604">
<a name="1740604"></a>Yoshikawa TT. Tuberculosis in Aging Adults. <i>J Am Geriatr Soc</i>. 1992;40(2):178-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/1740604/pubmed" id="1740604" target="_blank">1740604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22574487">
<a name="22574487"></a>Zaoui A, Abdelghani A, Ben Salem H, et al. Early-onset severe isoniazid-induced motor-dominant neuropathy: a case report. <i>East Mediterr Health J</i>. 2012;18(3):298-299. doi:10.26719/2012.18.3.298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22574487/pubmed" id="22574487" target="_blank">22574487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13393 Version 357.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
